Celyad lead compound in development, CAR T NKR-2, is currently being investigated in a second phase I in several oncology indications, five solid cancers and two hematological malignancies (Press release, Celyad, MAR 27, 2017, View Source [SID1234518583]).

This investigational therapy is based on a unique CAR T construct, with a multi-pronged mechanism of action, which is based on a receptor that can binds to ligands that are expressed in 80% of cancer, which makes CAR T NKR-2 applicable to both hematological and solid cancers.

Before clinical data are available, Celyad experts developed a White Paper that describes the technology and early clinical development of the CAR T NKR-2 platform and elucidates its fundamental differences with classical CAR-T technologies, which could reshape the frontiers of cell-based cancer immunotherapy.

Click here to access the fully referenced White paper, View Source